Read on Twitter
#Novacyt #NCYT $ALNOV Having been a shareholder since March 2020 I have been involved with a group of shareholders who have experienced the highs of £5 and then the decline to £2 during that time we continued to add as the research and understanding of the business was second to
none. We saw the highs of £12.50 and as it dropped we continued to add down to the low £7s. For me there are CEO who are shouting the loudest with too much substance however our belief in Graham is something I’ve never experienced before, a guy who hasn’t ramped the business to
be honest the total opposite Much to the frustrations of some shareholders. He’s taken the most sensible approach during the pandemic keep yourself out of the limelight keep innovating and investing in R&D. #NCYT have utilised their income to become debt free and plough into new
products and hire experienced individuals from blue chip companies to become part of the board building the foundations for the future. In my mind they are understanding what is needed to stay 1 step ahead of the curve something the big pharmas will be taking notice of. We will
see over the next few weeks / months this all come together and whilst the trading update wasn’t delivered well this goes back to the business being humble in their approach and just focus on the the importance of combating this pandemic. They are dealing with this spot on and
with the evolving board and increase of staff I feel these will prove even more important and exciting to how the business will evolve post pandemic. A long term hold for me and ATHs aren’t too far away.
